Home » Stocks » IMUX

Immunic, Inc. (IMUX)

Stock Price: $13.23 USD 0.26 (1.97%)
Updated May 10, 2021 2:55 PM EDT - Market open
Market Cap 282.09M
Revenue (ttm) n/a
Net Income (ttm) -70.06M
Shares Out 21.75M
EPS (ttm) -3.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $13.23
Previous Close $12.97
Change ($) 0.26
Change (%) 1.97%
Day's Open 12.92
Day's Range 12.07 - 13.49
Day's Volume 95,509
52-Week Range 9.00 - 28.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, May 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammato...

4 days ago - PRNewsWire

PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday.

Other stocks mentioned: CVAC, INO
3 weeks ago - Benzinga

NEW YORK, April 15, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamm...

3 weeks ago - PRNewsWire

NEW YORK, April 13, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic i...

3 weeks ago - PRNewsWire

NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology ther...

1 month ago - PRNewsWire

Immunic Inc's (NASDAQ: IMUX) lead candidate, IMU-838, has an “attractive safety profile” and exhibited positive efficacy results in the Phase II trials, according to JMP Securities. The Immunic Analyst:...

1 month ago - Benzinga

A simple yet effective way to screen stocks for investment ideas is to look at what the insiders are doing, and to keep an eye out for insider buying. The insiders are the people in a company who have a...

Other stocks mentioned: ASAN, BWEN, GE, KNSL, TUP
1 month ago - InvestorPlace

NEW YORK, March 2, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

2 months ago - PRNewsWire

NEW YORK, Feb. 26, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

2 months ago - PRNewsWire

Immunic Inc (NASDAQ: IMUX) has announced top-line data from an investigator-sponsored Phase 2 proof-of-concept trial evaluating IMU-838 in primary sclerosing cholangitis (PSC), a rare liver disease char...

2 months ago - Benzinga

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

2 months ago - PRNewsWire

Immunic Inc (NASDAQ: IMUX) completes the main analysis of Phase 1 CALVID-1 trial evaluating its lead asset, IMU-838. It is a selective oral DHODH inhibitor used in hospitalized patients with moderate CO...

2 months ago - Benzinga

NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

2 months ago - PRNewsWire

NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

2 months ago - PRNewsWire

NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inf...

4 months ago - PRNewsWire

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

4 months ago - PRNewsWire

NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

5 months ago - PRNewsWire

NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

5 months ago - PRNewsWire

NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

6 months ago - PRNewsWire

NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inf...

6 months ago - PRNewsWire

LUXEMBOURG and GRÄFELFING, Germany and NEW YORK, Oct. 20, 2020 /PRNewswire/ -- The European Investment Bank (EIB) and Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing ...

6 months ago - PRNewsWire

NEW YORK, Sept. 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic i...

7 months ago - PRNewsWire

NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic i...

7 months ago - PRNewsWire

NEW YORK, Sept. 8, 2020 /PRNewswire/ -- Immunic, Inc.

8 months ago - PRNewsWire

An analyst says buy.

8 months ago - The Motley Fool

NEW YORK, Aug. 4, 2020 /PRNewswire/ -- Immunic, Inc.

9 months ago - PRNewsWire

NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Immunic, Inc.

9 months ago - PRNewsWire

Immunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Immunic Inc (NASDAQ: IMUX) shares are surging following a positive clinical readout.

9 months ago - Benzinga

NEW YORK, July 30, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamma...

9 months ago - PRNewsWire

NEW YORK, July 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamma...

9 months ago - PRNewsWire

NEW YORK, July 27, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamma...

9 months ago - PRNewsWire

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Other stocks mentioned: BCRX, BNTX, BSGM, CYDY, EIGR, GILD, PFE ...
9 months ago - Seeking Alpha

NEW YORK, June 22, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamma...

10 months ago - PRNewsWire

NEW YORK, June 15, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamma...

10 months ago - PRNewsWire

Immunic (IMUX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this year.

11 months ago - Zacks Investment Research

NEW YORK, June 10, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamma...

11 months ago - PRNewsWire

NEW YORK, June 9, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammat...

11 months ago - PRNewsWire

NEW YORK, June 9, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammat...

11 months ago - PRNewsWire

NEW YORK, May 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammat...

11 months ago - PRNewsWire

NEW YORK, May 19, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammat...

11 months ago - PRNewsWire

About IMUX

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intes... [Read more...]

Industry
Biotechnology
CEO
Daniel Vitt
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
IMUX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Immunic stock is "Buy." The 12-month stock price forecast is 59.38, which is an increase of 349.00% from the latest price.

Price Target
$59.38
(349.00% upside)
Analyst Consensus: Buy